恩替卡韦对慢性乙型肝炎外周血Th9/Treg的影响  

Effects of entecavir on peripheral blood Th9/Treg in patients with chronic hepatitis B

作　　者：郭艳[1] 李华铭[1] 王宇芳[1] 李春霞[1] 刘肄辉[2] GUO Yan;LI Huaming;WANG Yufang;LI Chunxia;LIU Yihui(Department of Gastroenterology,Hangzhou Third Peopleʼs Hospital,Hangzhou 310009,China;Department of Digestive Hepatology,Hangzhou Red Cross Hospital,Hangzhou 310003,China)

机构地区：[1]杭州市第三人民医院消化科,浙江杭州310009 [2]杭州市红十字会医院消化肝病科,浙江杭州310003

出　　处：《中国现代医生》2022年第33期78-81,102,共5页China Modern Doctor

基　　金：浙江省自然基金项目(Y2110708);杭州市科技计划项目(20181228Y08)。

摘　　要：目的观察恩替卡韦抗病毒治疗对慢性乙型肝炎外周血辅助性T细胞(helper T cells,Th)9/调节性T细胞(regulatory T cells,Treg)的影响。方法收集杭州市第三人民医院2019年1月至2020年1月符合抗病毒治疗指征的慢性乙型肝炎患者40例,予恩替卡韦(0.5mg/d)抗病毒治疗,观察时间24周,治疗前后分别检测血清肝功能、乙型肝炎病毒脱氧核糖核酸(hepatitis B virus deoxyribonucleic acid,HBV-DNA)、外周血Th9细胞频数、Treg细胞频数等指标,观察抗病毒疗效与外周血Th9/Treg的关系。结果恩替卡韦治疗前后丙氨酸氨基转移酶(alanine transaminase,ALT)、HBV-DNA、Th9、Treg、Th9/Treg比较,差异均有统计学意义(P<0.05);治疗24周后ALT复常33例,未复常7例,两组ALT、Th9、Treg、Th9/Treg比较,差异均有统计学意义(P<0.05);治疗24周后HBV-DNA转阴34例,未转阴6例,两组HBV-DNA、Treg、Th9/Treg比较,差异均有统计学意义(P<0.05)。结论恩替卡韦抗病毒治疗可降低外周血Th9、Treg水平,Th9/Treg比值降低,与疗效相关。Objective To observe the effect of entecavir antiviral therapy on peripheral blood Th9/Treg of chronic hepatitis B.Methods A total of 40 patients with chronic hepatitis B conforming to antiviral therapy indications were collected from Hangzhou Third People's Hospital from January 2019 to January 2020.They were treated with entecavir(0.5mg/d)for 24 weeks.Serum liver function,HBV-DNA,peripheral blood Th9 cell frequency,Treg cell frequency and other indicators were detected before and after treatment,and the relationship between antiviral efficacy and peripheral blood Th9/Treg was observed.Results There were statistically significant differences in ALT,HBV-DNA,Th9,Treg and Th9/Treg before and after entecavir treatment(P<0.05).After 24 weeks of treatment,33 cases returned to normal ALT,and 7 cases did not return to normal ALT.There were statistically significant differences in ALT,Th9,Treg and Th9/Treg between the two groups(P<0.05).After 24 weeks of treatment,34 cases turned negative for HBV-DNA,and 6 cases did not.There were statistically significant differences in HBV-DNA,Th9,Treg,and Th9/Treg between the two groups(P<0.05).Conclusion Entecavir antiviral treatment can reduce the levels of Th9 and Treg in peripheral blood,and the Th9/Treg ratio decreases,which is related to the efficacy.

关 键 词：慢性乙型肝炎 TH9细胞 TREG细胞 恩替卡韦 抗病毒治疗 

分 类 号：R743[医药卫生—神经病学与精神病学]